Home / Business News

Business News

HitGen Enters Innovative Drug Discovery Research Collaboration with LG Chem by Applying DNA-Encoded Technology

CHENGDU, China, Aug. 17, 2018 (GLOBE NEWSWIRE) — HitGen Ltd today announced a multi-year major drug discovery research collaboration with LG Chem to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening …

Read More »

Merck and Healthy Interactions Launch Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management

KENILWORTH, N.J., Aug. 17, 2018 /PRNewswire/ — Healthy Interactions, a global leader in health education, in collaboration with Merck (NYSE : MRK ), known as MSD outside the United States and Canada, today announced the launch of map4health™ – a digital platform and mobile application in the U.S. that was …

Read More »

Novo Nordisk Acquires Ziylo, Gaining Innovative Technology Platform that Could Accelerate Development of New Diabetes Treatment

BRISTOL and COPENHAGEN, 17 August 2018 ­- Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology – …

Read More »

BioNTech Enters Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

MAINZ, Germany & NEW YORK–(BUSINESS WIRE)–BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of …

Read More »

Natera and Fox Chase Cancer Center to Collaborate to Assess the Signatera Customized ctDNA Assay for Monitoring Kidney Cancer

SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company’s Signatera™ (Research-Use Only) customized circulating tumor DNA (ctDNA) assay for …

Read More »

RXi Pharmaceuticals Partners with Karolinska Institutet to Develop sd-rxRNA Compounds to Advance Immuno-Oncology Therapeutics

MARLBOROUGH, Mass., Aug. 15, 2018 /PRNewswire/ — RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it has entered into a research collaboration with the Karolinska Institutet in Stockholm, Sweden. This collaboration …

Read More »

Novocure and US Oncology Research Collaborate on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

ST. HELIER, Jersey & THE WOODLANDS, Texas–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. Tumor Treating Fields is a cancer therapy that uses …

Read More »

Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE:CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the successful completion of the previously announced tender offer by Catalent Boston, Inc. (“Merger Sub”), a subsidiary of Catalent Pharma Solutions, Inc. (“Parent”), Catalent’s …

Read More »

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

GAITHERSBURG, Md., Aug. 13, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of $270 million. PaxVax is majority owned …

Read More »

Sarepta Expands its Presence in Gene Therapy through Investment and License Agreement with Lacerta

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that it has made a strategic investment and entered into a license and option agreement with Lacerta Therapeutics, a gene …

Read More »